Article

The big picture of rapid blood culture identification

Published on April 30, 2024 | 5 min read

Key takeaways

Assess the analytical performance of all three of the cobas eplex BCID panels for the rapid identification of gram-negative, gram-positive, and fungal pathogens
Describe how the rapid results from the cobas eplex BCID panels could have changed the management of patients with bacteremia or fungemia
Examine the results of a randomized clinical trial assessing the medico-economic and clinical evaluation of the cobas eplex BCID panels in patients with bloodstream infections

A retrospective clinical analysis building to a prospective clinical trial

During this webinar, Dr. Yvan Caspar will describe in detail two complementary studies performed at the Centre Hospitalier Universitaire Grenoble Alpes (CHUGA) using the trio of cobas^® eplex blood culture identification panels for detection of bloodstream infections caused by gram-negative, gram-positive, and fungal pathogens. First, he will discuss the results of a retrospective study that assessed the analytical performance of the cobas eplex BCID panels and the potential clinical outcomes based on these results.

For each positive blood culture included in the study, the patient’s health record was retrospectively reviewed by a clinical team to assess how the rapid detection of pathogens and antimicrobial resistance genes from positive blood cultures, using the cobas eplex BCID panels, would have potentially changed the management of patients with bloodstream infections.

Dr. Caspar will then highlight initial data that has been collected and analyzed from the HEMOFAST prospective randomized clinical trial, which is a clinical and medico-economic evaluation of the cobas eplex BCID panels for the diagnosis of bacteremia and fungemia compared to conventional microbiology. While the trial was still in progress, preliminary data was presented to provide a glimpse into the benefits of the cobas eplex BCID panels.

As the body of scientific literature for faster identification and management of bloodstream infections grows, the data generated at CHUGA continues to expand the evidence supporting the clinical utility of these technologies. The two studies being showcased in this webinar will provide a big-picture view of how the cobas eplex BCID panels are improving rapid blood culture diagnostics.

Using cobas^® eplex BCID panels for detection of bloodstream infections

Update Required To play the media you will need to either update your browser to a recent version or update your Flash plugin.

Meet the speaker

Yvan Caspar — PhD, PharmD

Yvan Caspar is a clinical microbiologist at the bacteriology laboratory of Grenoble Alpes University Hospital (2,100 beds), which also hosts the French National Reference Center for Francisella.

His main research focuses on Francisella and tularemia, antibiotic resistance and on the development of new therapeutic strategies. He is also interested in innovative rapid diagnosis technologies, in particular, techniques to improve the management of sepsis and antibiotic stewardship.

Contact us

Do you have questions about our products or services? We’re here to help. Contact a Roche representative in your region.

Contributors

Roche Diagnostics

Roche Diagnostics is a division of Roche, developing and integrating diagnostic solutions that address today’s healthcare challenges while anticipating tomorrow’s needs. In more than 100 countries, we provide one of the industry’s most comprehensive in vitro diagnostics portfolios spanning molecular diagnostics, clinical chemistry and immunoassays, tissue diagnostics, Point of Care testing, patient self-testing, next-generation sequencing, laboratory automation and IT, as well as digital health and decision-support solutions.

Our articles are authored by Roche Diagnostics subject matter experts, drawing on collective expertise across multiple disciplines to provide reliable insights for healthcare professionals worldwide.

Learn more